News
Apr 06, 2026
Swelling and fluid retention are common symptoms for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). This condition causes the heart muscle to…
Apr 02, 2026
NICE(UK): Acoramidis can be used, within its marketing authorisation, as an option to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in…
Mar 28, 2026
I would like to attend…Live In Person in New OrleansSaturday, March 28, 20266:30-7:00 AM CDT: Registration & Breakfast7:00-8:00 AM CDT: SymposiumVirtually…
Mar 27, 2026
Fresh funding backs a high-stakes attempt to do what current amyloidosis drugs still cannot: clear the buildup already damaging the heart.UK-based biotech Immutrin…
Mar 25, 2026
Viz.ai has announced a partnership with Alnylam Pharmaceuticals to improve early identification and care coordination for patients with cardiac amyloidosis, a…
Mar 25, 2026
Join the CCS for the third and final installment of the Amyloid Education Series 2.0 in the upcoming webinar, ‘Cases and Clinical Conundrums in Amyloidosis…